AbbVie has announced a $1.4 billion investment to build a 185-acre pharmaceutical manufacturing campus in Durham, North Carolina in the US. The state-of-the-art campus will integrate advanced manufacturing and laboratory technologies with artificial intelligence (AI) to support the production of AbbVie's immunology, neuroscience and oncology medicines.
This is AbbVie's first major investment in North Carolina. The AbbVie Durham campus, located near Research Triangle Park, was selected for the strength of the region's local workforce and its ability to support future expansion. Construction will begin this year, with completion expected by the end of 2028.
Over the next four years, AbbVie plans to hire 734 people, including engineers, scientists, manufacturing operators and laboratory technicians. The project will also support the local economy by generating more than 2,000 construction jobs during campus development.
This project is part of the company's $100 billion commitment to US R&D and capital investments, including manufacturing, over the next decade. The first phase of construction will include small volume parenteral (SVP) drug product manufacturing facilities, next-generation laboratories, a warehouse, administrative offices and employee wellness facilities with room to support AbbVie's growing pipeline.
